Compare Colgate-Palmolive Company (CL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs TransMedics Group Inc — how do they compare? Colgate-Palmolive Company trades at $91.83 (market cap $72.84B), while TransMedics Group Inc trades at $75.64 (market cap $2.58B). The key difference: Colgate-Palmolive Company is far larger — about 28.2× TransMedics Group Inc's market cap, and Colgate-Palmolive Company pays a 2.33% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CL | TMDX | |
|---|---|---|
Market Cap | $72.84B | $2.58B |
Sector | Consumer Staples | Technology |
52-Week High | $99.14 | $150.42 |
52-Week Low | $74.98 | $61.99 |
Enterprise Value | $79.48B | $2.98B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.21, up 1.05% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 60.06% gross margins and 822.05% ROE, though valuation metrics appear elevated with a P/E of 36.13. Recent dividend declarations and positive analyst coverage (42% buy rating) support the defensive stock's appeal amid market rotation into stable cash flow names.
Outlook remains positive with a $97 consensus price target representing 4% upside, though premium valuation and North American segment softness present headwinds. The company's 64-year dividend growth streak and global diversification provide stability, while inflation pressures and competitive threats require monitoring for sustained outperformance.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
